UNSPSC 51141571: Phensuximide

This classification denotes an anticonvulsant agent with the molecular formula C11H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WVL9C355G, chemically known as 2,5-pyrrolidinedione, 1-methyl-3-phenyl- but generally known as phensuximide, which bears US NIH Compound Identifier 6839. European Medicines Agency schedules Phensuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09783MIG.

UNSPSC 51141571 Phensuximide is a Commodity code that nominally identifies a specific anticonvulsant pharmaceutical, but the recent state and local opportunities tagged under it reveal a much broader purchasing pattern: state and local health authorities are acquiring naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing arrangements. The work spans pharmaceutical supply contracts, emergency medical countermeasures, and participation in multi-state cooperative drug procurement frameworks that serve public health systems, employee health plans, and community health initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that bundle procurement across participating states and local jurisdictions. These are primarily health department and state agency buyers rather than school districts or transit authorities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) across participating state and local facilities. The MMCAP solicitation requires vendors to hold $5,000,000 in commercial general liability coverage, comply with current Good Manufacturing Practices and Drug Supply Chain Security Act standards, and accept a 3 percent administrative fee; award values are not disclosed but performance penalties range from $200 to $1,500 per violation.